Ozempic Is Not The Most Effective Weight-Loss Drug On The Market, Reveals A Study

In a recent large-scale analysis of real-world data, the blockbuster diabetes drug Mounjaro was found to be more effective for weight loss than the highly popular Ozempic in overweight or obese adults.

Growing Demand for Weight Loss Treatments

The study's findings come when drugs and similar treatments approved for weight loss, including Mounjaro and Ozempic, are experiencing increased demand in the U.S. for their ability to help individuals shed unwanted pounds.

Off-Label Use for Weight Loss

While Mounjaro and Ozempic are approved for treating type 2 diabetes, many people use these weekly injections off-label to manage their weight. The study delves into the comparative effectiveness of these drugs, shedding light on their real-world impact.

Insights from Truveta Research

Between May 2022 and September 2023, 18,000 adults who were overweight or obese and started Mounjaro or Ozempic treatment were the subject of a Truveta Research study that examined healthcare data. The research indicates that Mounjaro holds an edge over Ozempic, particularly among adults who are overweight or obese.

Key Findings on Weight Loss and Diabetes Management

Patients taking Mounjaro were significantly more likely to achieve weight loss milestones than those on Ozempic, with more significant reductions in body weight observed at various intervals. Interestingly, the study notes that head-to-head clinical trials for this population are unavailable.

Weekly Injections and the Dual Approach

Both Mounjaro and Ozempic, along with their weight-loss counterparts, are weekly injections that influence appetite by mimicking certain hormones in the gut. Mounjaro's unique dual approach, mimicking both GLP-1 and GIP, sets it apart and potentially contributes to more substantial weight loss.

Implications for Patient Care

The study's findings aim to inform patient care by offering insights into the comparative effectiveness of Mounjaro and Ozempic, addressing weight loss concerns for those with type 2 diabetes.

Unsplash

Looking Ahead: Ongoing Clinical Trials

Eli Lilly is currently conducting clinical trials for the weight-loss counterparts of Mounjaro and Ozempic—Zepbound and Wegovy. Results are anticipated in 2025, providing further insights into these drugs' impact on obese or overweight patients.

In conclusion, this study contributes valuable real-world data, helping individuals and healthcare professionals make informed decisions regarding weight loss treatments and their effectiveness.

For more trending stories, follow us on?Telegram.